Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

Expertise Smart home devices, outdoors gadgets, smartphones, wearables, kid's tech, and some dabbling in 3D printing Credentials Covered the mobile and smart home tech space for the past five ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to crown any winners in the race for the next generation of anti-obesity ...

The best smart home devices can raise your home's IQ, from security cameras and Wi-Fi locks to smart light bulbs. When you purchase through links on our site, we may earn an affiliate commission.

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

In this case, the culprit was CagriSema, the company’s potential next-generation weight-loss treatment. Novo had set a target for patients to lose 25% of their body weight on average over 68 weeks.

Well, it was the age-old bane of pharma firms, namely disappointing late-stage clinical trial results. In this case, the culprit was CagriSema, the company’s potential next-generation weight-loss ...

Novo Nordisk's dosing in CagriSema obesity drug trial puzzles ... banking on sustained demand for its medical devices in the United States. Medtronic lifts annual profit view on steady demand ...

(Ralf Groene via LinkedIn). Ralf Groene, a key figure in the design of Microsoft’s devices for more than 17 years, has emerged from a short-lived retirement with a new role, as the vice ...

What I got instead was a nuanced, well-thought-out device that just might make personalized AI a real thing. Bee is a relatively inexpensive wrist wearable, about the same size and shape as a ...

Apple's slate of 2025 products look to be dominated by a large number of low-cost and entry-level devices. Here's what to expect. With advancements like Apple Intelligence and all-new in-house ...